Literature DB >> 11360246

Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.

I Tsuge1, T Morishima, H Kimura, K Kuzushima, H Matsuoka.   

Abstract

Clinical evidence of a relationship between severe chronic active Epstein-Barr virus (EBV) infection and clonal expansion of EBV-infected T or NK cells has been accumulated. In order to clarify pathogenesis of EBV-infected cell proliferation in patients with severe chronic active EBV infection, cytotoxic T lymphocyte (CTL) responses of two patients against B-lymphoblastoid cell lines (B-LCL) and EBV-infected NK cells were examined in comparison with those of HLA-identical healthy siblings. Unexpectedly, patients' CTL activities induced by mixed culture with autologous B-LCLs were markedly reduced, although uncontrolled EBV-related B-cell proliferations have never been experienced. In contrast, limiting dilution analysis demonstrated that B-LCL-specific CTL precursor (CTLp) frequencies of patients were comparable to those of their healthy sisters. The existence of normal levels of B-LCL-specific T cell responses was confirmed by flow-cytometric analysis of IFN-gamma-producing T cells after stimulation with B-LCLs. Infected NK-cell-specific CTLp frequencies of the patients were at undetectable levels despite their expression of latent membrane protein (LMP) 1, suggesting mechanisms to escape immunologic surveillance. In the patients' HLA-identical healthy sisters, infected NK-cell-specific CTLps were detected, and infected NK-cell-specific CTL clones could be established. From these findings, two treatment options for severe chronic active EBV infection are offered for consideration: adoptive transfer of in vitro-cultured CTL, and bone marrow transplantation from HLA-identical donors. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11360246     DOI: 10.1002/jmv.1029

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Successful reduced-intensity stem cell transplantation with cord blood for a poor-prognosis adult with refractory chronic active epstein-barr virus infection.

Authors:  Masao Nakagawa; Satoshi Hashino; Mutsumi Takahata; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Sachiko Ando; Masahiro Asaka
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

2.  A formal analysis of cytokine networks in chronic fatigue syndrome.

Authors:  Gordon Broderick; Jim Fuite; Andrea Kreitz; Suzanne D Vernon; Nancy Klimas; Mary Ann Fletcher
Journal:  Brain Behav Immun       Date:  2010-05-04       Impact factor: 7.217

3.  Optimal treatment for chronic active Epstein-Barr virus disease.

Authors:  Jeffrey I Cohen
Journal:  Pediatr Transplant       Date:  2009-06

4.  Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells.

Authors:  Ken-ichi Imadome; Misako Yajima; Ayako Arai; Atsuko Nakazawa; Fuyuko Kawano; Sayumi Ichikawa; Norio Shimizu; Naoki Yamamoto; Tomohiro Morio; Shouichi Ohga; Hiroyuki Nakamura; Mamoru Ito; Osamu Miura; Jun Komano; Shigeyoshi Fujiwara
Journal:  PLoS Pathog       Date:  2011-10-20       Impact factor: 6.823

Review 5.  EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.

Authors:  Stefan D Dojcinov; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Pathogens       Date:  2018-03-07

6.  Generalized myositis mimicking polymyositis associated with chronic active Epstein-Barr virus infection.

Authors:  Tomoyuki Uchiyama; Kimito Arai; Takako Yamamoto-Tabata; Kanji Hirai; Kouji Kishimoto; Yoshiko Nakamura; Takamichi Hattori
Journal:  J Neurol       Date:  2005-03-04       Impact factor: 6.682

Review 7.  Chronic Active Epstein-Barr Virus Disease.

Authors:  Hiroshi Kimura; Jeffrey I Cohen
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.